FibroBiologics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
FibroBiologics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2023 to Q3 2024.
  • FibroBiologics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$3.35M, a 63.4% decline year-over-year.
  • FibroBiologics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$12.5M.
  • FibroBiologics, Inc. annual Operating Income (Loss) for 2023 was -$8.89M, a 99% decline from 2022.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$12.5M -$3.35M -$1.3M -63.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$11.2M -$3.22M -$1.13M -54% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$10.1M -$3.45M -$1.19M -52.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$8.89M -$2.48M Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 -$2.05M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$2.09M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$2.27M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.